Palobiofarma S.L.

Who We Are
Palobiofarma S.L. is a Spanish biotechnology company based in Navarra and management offices in Barcelona, founded in 2005 by a team of scientists with extensive experience in drug discovery within the pharmaceutical industry. Our mission is to develop innovative drugs targeting adenosine receptors, with the vision of bringing the first selective modulator of these receptors to market.

Areas of Expertise
Palobiofarma leverages its expertise in virtual drug design, medicinal chemistry, and in vitro pharmacology to advance its research. While we focus our internal resources on compound characterization and intellectual property, we collaborate with CROs, research centers, and universities to conduct essential pharmacology and toxicology studies, ensuring a comprehensive approach to drug development. Currently, the company is engaged in intense clinical activity, as all its products in development are in the clinical phase, most of them in Phase II.

Development and Funding
Palobiofarma is a biotechnology SME that has successfully secured both private and public funding to support its developments. The company has raised €11 million in seven rounds of private capital investment, with key participation from Inveready Seed Capital, FIT Inversión en Talento, and the Sociedad de Desarrollo de Navarra (SODENA). Additionally, we have received €7.9 million in public funding, including €6.7 million in grants in the form of loans. A notable example of funding is the European Union’s EIC Accelerator program, which supported the advanced development of our compound PBF-680, leading to the completion of a Phase 2 clinical trial in patients with Chronic Obstructive Pulmonary Disease (COPD).

Product Pipeline
Currently, Palobiofarma has a pipeline of seven products, all in clinical development for various indications, including autoimmune diseases, respiratory conditions, and cancer.

Business Model Validation
Our business model has been validated through high-value agreements with leading industry players. We have licensed PBF-680 to NOVARTIS and sold royalties to XOMA, demonstrating the commercial viability of our innovations.

Palobiofarma S.L. with a strong patents portfolio is positioned as an innovative and leading company in the development of drugs based on the modulation of adenosine receptors. Thanks to our collaborative strategy, strong scientific foundation, and financial backing from both private investors and public institutions, we continue advancing in the development of groundbreaking therapies to improve patients’ quality of life.